Skip to main content

Table 4 Prevalence of k13 mutations by study

From: Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies

k13 genotype

Muse 2011–12

Tamu 2012

Tabeikkyin 2014

Tamu 2014

Grand total n (%)

AL n

AS + MQ n

Total n (%)

AL n

AS + MQ n

Total n (%)

AL n

DP n

Total n (%)

DP n (%)

F446I

1

8

9 (12.7)

19

6

25 (25.8)

10

6

16 (25.4)

14 (24.6)

64 (22.2)

N458Y

0

0

0 (0)

0

0

0 (0)

3

4

7 (11.1)

0 (0)

7 (2.4)

S459L

0

0

0 (0)

0

0

0 (0)

0

1

1 (1.6)

0 (0)

1 (0.3)

P553L

0

0

0 (0)

0

1

1 (1)

1

0

1 (1.6)

0 (0)

2 (0.7)

R561H

1

1

2 (2.8)

0

0

0 (0)

3

3

6 (9.5)

7 (12.3)

15 (5.2)

P574L

5

0

5 (7)

0

1

1 (1)

0

0

0 (0)

0 (0)

6 (2.1)

A676D

0

0

0 (0)

0

1

1 (1)

0

0

0 (0)

0 (0)

1 (0.3)

P701R

1

0

1 (1.4)

0

0

0 (0)

0

0

0 (0)

0 (0)

1 (0.3)

Total k13 mutations

8

9

17 (23.9)

19

9

28 (28.9)

17

14

31 (49.2)

21 (36.8)

97 (33.7)

Wild type

38

16

54 (76.1)

41

28

69 (71.1)

16

16

32 (50.8)

36 (63.2)

191 (66.3)

Total cases genotyped

46

25

71

60

37

97

33

30

63

57

288